News | January 07, 2025
Japan Health Authority approves Biocon Biologics’ Ustekinumab BS, Biosimilar to J&J's Stelara
The biosimilar Ustekinumab has been developed and manufactured by the company
The biosimilar Ustekinumab has been developed and manufactured by the company
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Merck will record a pre-tax charge relating to the upfront payment of $588 million
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Merck has also decided to end the favezelimab clinical development program
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Subscribe To Our Newsletter & Stay Updated
